Inhibikase Therapeutics (IKT) Cash & Equivalents (2020 - 2026)

Inhibikase Therapeutics (IKT) has reported Cash & Equivalents for 7 consecutive years, with $49.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 32.5% year-over-year to $49.6 million; the TTM figure through Mar 2026 stood at $49.6 million (down 32.5% YoY), while the FY2025 annual figure was $139.2 million, up 146.45% from the prior year.
• Cash & Equivalents eased to $49.6 million in Q1 2026 per IKT's latest filing, from $139.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $139.2 million in Q4 2025 and bottomed at $913420.0 in Q3 2024.
• Historically, Cash & Equivalents has averaged $32.5 million across 5 years, with a median of $14.9 million in 2023.
• Annual changes were most pronounced in 2023 — Cash & Equivalents tumbled 94.09% — and 2025, when it soared 4089.72%.
• Inhibikase Therapeutics' Cash & Equivalents stood at $7.2 million in 2022, then advanced by 27.5% to $9.2 million in 2023, then jumped by 516.36% to $56.5 million in 2024, then soared by 146.45% to $139.2 million in 2025, then tumbled by 64.39% to $49.6 million in 2026.
• Business Quant data shows IKT's Cash & Equivalents at $49.6 million in Q1 2026, $139.2 million in Q4 2025, and $38.3 million in Q3 2025.